Артериальная гипертензия у женщин. Есть ли основаниядля особой тактики лечения?

1. Thom T, Haase N, Rosamond W et al. Heart disease and stroke statistics – 2006 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 2006; 113: e85–151.
2. Mosca L, Appel LJ, Benjamin EJ et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004; 109: 672–93.
3. Mosca L, Grundy SM, Judelson D et al. Guide to preventive cardiology in women. Circulation 1999; 99: 2480–4.
4. Профилактика, диагностика и лечение первичной артериальной гипертонии в Российской Федерации. Первый доклад экспертов научного общества по изучению артериальной гипертонии Всероссийского научного общества кардиологов и Межведомственного совета по сердечно-сосудистым заболеваниям (ДАГ 1). Клин. фарм. тер. 2000; 3: 1–22.
5. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Росс. кардиол. журн. 2006; 4: 45–50.
6. Быстрова М.М., Бритов А.Н. Артериальная гипертония у женщин в постменопаузе. Кардиология. 1999; 5: 72–80.
7. Оганов Р.Г. Эпидемиология артериальной гипертонии в России и возможности профилактики. Тер. арх. 1997; 69 (8): 66–9.
8. Oparil S, Yiu-Fai Chen. Cardiovascular disease in women: overview. In: Hypertension after menopause. Ed. M.Stimpel, A.Zanchetti. Berlin – New York: Walter de Gruyter, 1997; р. 3–19.
9. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997; 18 (10): 1569–82.
10. Брагина А.Е. Роль дифференцированной заместительной гормональной терапии в лечении артериальной гипертензии у женщин в перименопаузе. Автореф. дис. … канд. мед. наук. М., 2000.
11. Баранова Е.И. Гипертоническая болезнь у женщин в постменопаузе: особенности клинических проявлений, патогенеза и лечения. Автореф. дис. … д-ра мед. наук. СПб., 1998.
12. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–9.
13. Toth MJ, Sites CK, Eltabbakh GH, Poehlman ET. Effect of menopausal status on insulin-stimulated glucose disposal: comparison of middle-aged premenopausal and early postmenopausal women. Diabetes Care 2000; 23: 801–6.
14. Мамедов М.Н., Оганов Р.Г. Эпидемиологические аспекты метаболического синдрома. Кардиология. 2004; 9: 15.
15. Руководство по климактерию. Под ред. В.П.Сметник, В.И.Кулакова. М.: Медицинское информационное агентство, 2001.
16. Devereux RB, Savage PD, Saclis I, Laragh JH. Relation of hemodynamic load to left ventricular hypertrophy and performance in hypertension. Am J Cardiol 1983; 51: 171–6.
17. Hammond IW, Devereux RB, Alderman MH et al. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 1986; 7: 639–50.
18. Kannel WB. Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens 1991; 9 (Suppl. 2): S3–9.
19. Krumbolz H, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol 1993; 72: 310–3.
20. Фомина И.Г., Брагина А.Е., Гайдамакина Н.Е., Салимжанова Ю.Н. Почечная гемодинамика и клубочковая фильтрация у больных с гипертонической болезнью в возрасте 40–60 лет. Рациональная тер. в кардиол. 2007; 5: 69–72.
21. Murabito JM, Evans JS, Larson MG, Levy D. Prognosis after the onset of coronary heart disease. An investigation of differences in outcome between the sexes according to initial coronary disease prevention. Circulation 1993; 88: 548–55. Heart disease and stroke statistics – 2003 update. Dallas: American Heart Association. 2002.
22. Manolio T, Kronmal R, Burke G et al. Short-term predictors of incident stroke in older adults. The Cardiovascular Health Study. Stroke 1996; 27 (9): 1479–86.
23. Болдуева С.А., Третьякова Н.С., Матвеев Д.Г. Ишемическая болезнь у женщин: только ли возрастные различия с мужчинами? Пробл. жен. здоровья. 2006; 1: 64–77.
24. Wassertheil-Smoller S, Anderson G, Psaty BM et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women’s Health Initiative. Hypertension 2000; 36: 780–9.
25. Al-Azzawi F. The menopause and its treatment in perspective. Postgrad Med 2001; 77 (907): 292–304.
26. Lewis CE, Grandits GA, Flack J et al. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Arch Intern Med 1996; 156: 377–85.
27. Fishman EZ, Tenenbaum A, Pines A. Systemic hypertension in postmenopausal women: a clinical approach. Curr Hypertens Rep 2002; 4: 464–70.
28. Lonn E, Roccaforte R, Yi Q et al. Effects of long-term therapy with ramipril in high risk women. J Am Coll Cardiol 2002; 40: 693–702.
29. Dahlof B, Dereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.
30. Чазова И.Е., Сметник В.П., Балан В.Е. и др. Ведение женщин с сердечно-сосудистым риском в пери- и в постменопаузе: консенсус российских кардиологов и гинекологов. Consilium Medicum 2007; 10 (6).
31. Mackay FJ, Pearce GL, Mann RD. Cough and angiotensin II receptor antagonists: cause or confounding? Br J Clin Pharmacol 1999; 47: 111–4.
32. Strocchi E, Malini PL, Valtancoli G et al. Cough during treatment with angiotensin-converting enzyme inhibitors. Analysis of predisposing factors. Drug Invest 1992; 4: 69–72.
33. Thawornkaiwong A, Preawnim S, Wattanapermpool J. Upregulation of β1-adrenergic receptors in ovariectomized rat hearts. Life Sci 2003; 72: 1813–24.
34. Labbe L, Sirois C, Pilote S et al. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 2000; 10: 425–38.
35. Luzier AB, Killian A, Wilton JH et al. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 1999; 66: 594–601.
36. Walle T, Walle K, Mathur RS et al. Propranolol metabolism in normal subjects: association with steroid hormones. Clin Pharmacol Ther 1994; 56: 127–32.
37. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P-450 3A substrates. Clin Pharmacokinet 2005; 44: 33–60.
38. Krecic-Shepard ME, Park K, Barnas C et al. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 2000; 68: 130–42.
39. Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol 2001; 2: 349–51.
40. ALLHAT Collaborative Research Group, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting ensyme inhibitor or calcium channel blocker vs diuretic. JAMA 2000; 288: 2981–97.
41. Rosenthal T, Oparil S. Hypertension in women. J Hypertens 2000; 14 (10–11): 691–704.
42. Wasnish RD, Davis JW, He YF et al. A randomized, double-masked, placebo-controlled trial of chlorthalidone and bone loss in elderly women. Osteoporosis Int 1995; 5 (4): 247–51.
43. Felson DT, Sloutskis D, Anderson JJ et al. Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study. JAMA 1991; 265 (3): 370–3.
44. Morton DJ, Barrett-Connor EL, Edelstein SL. Thiazide and bone mineral density in elderly men and women. Am J Epidemiol 1994; 139 (11): 1107–15.
45. Reid IR, Ames RW, Orr-Walker BJ et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med 2000; 109 (5): 362–70.
46. Edwards BR, Baer PG, Sutton RA. Micropuncture study of diuretic effects on sodium and calcium reabsorption in the dog nephron. J Clin Invest 1973; 52: 2418–27.
47. Schoofs MW, van der Klift M, Hofman A et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003; 139: 476–82.
48. Mosca L, Banka CL, Benjamin EJ et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update. Circulation 2007; 115: 1481–501.
49. Calhoun DA, Oparil S. Gender and blood pressure. In: Hypertension primer. Izzo JL, Black HR. (eds). Dallas 2003; 253–7.
50. Grimm RHJr. Antihypertensive therapy: taking lipids into consideration. Am Heart J 2001; 122: 910–8.
51. Подзолков В.И. Использование арифона ретард для лечения артериальной гипертензии у женщин после гистерэктомии с сохранением придатков. Актуальн. вопр. артериальн. гипертен. 2004; 10: 8–10.
52. Gosse P, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1,5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18: 1465–75.
53. Marre M, Puig JG, Kokot F еt al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J Hypertens 2004; 22: 1613–22.
54. London G, Asmar R, Schmieder R, Calvo C. Antihypertensive efficacy of Indapamide SR vs candesartan and amlodipine in hypertensive patients in isolated hypertensive patients. Am J Hypertens 2004; 17 (5): 183А.
55. Чазова И.Е., Мычка В.Б. Открытая, многоцентровая, рандомизированная, научно-практическая программа МИНОТАВР: промежуточный анализ результатов. Кардиоваскул. тер. и профилак. 2006; 5 (2): 81–8.
56. Bair D, Beisher NA, Bygdeman M et al. Clinical Obstetrics and Gynecology 1988; 2: 66–72.
57. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl JMed 2008; 358: 1887–98.
58. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolate systolic hypertension: the final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 26: 3255–64.
59. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757–64.

В.И.Подзолков, А.Е.Брагина, Ю.Н.Родионова,Е.К.Панферова